lapatinib has been researched along with lovastatin in 5 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (lovastatin) | Trials (lovastatin) | Recent Studies (post-2010) (lovastatin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 4,828 | 698 | 873 |
| Protein | Taxonomy | lapatinib (IC50) | lovastatin (IC50) |
|---|---|---|---|
| Chain A, Antigen Cd11a (p180) | Homo sapiens (human) | 2.4 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.0261 | |
| Integrin beta-2 | Homo sapiens (human) | 3.09 | |
| Intercellular adhesion molecule 1 | Homo sapiens (human) | 3.78 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 8.753 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 10 | |
| Neutrophil elastase | Homo sapiens (human) | 0.027 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.02 | |
| Integrin alpha-L | Homo sapiens (human) | 3.09 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 8.753 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.02 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0529 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hou, S; Lei, H; Li, Q; Liu, F; Liu, H; Liu, S; Wang, D; Wang, S; Wang, T; Wu, Y; Xu, L; Zaky, MY; Zhang, J; Zhang, Y; Zou, K; Zou, L | 1 |
1 review(s) available for lapatinib and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 other study(ies) available for lapatinib and lovastatin
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cholesterol; Drug Synergism; Endocytosis; Female; Filipin; Humans; Lapatinib; Lovastatin; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Proteolysis; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2019 |